Tags: tremfya vs taltz

The latest breaking news and top news headlines at 5sa.xyz

Heathbridge Capital Management LTD Continues to Hold Holding in Sierra Wireless (SWIR); Lilly Eli & Co (LLY) Holder Cibc World Markets Has Lifted Its Position by $5.57 Million
Heathbridge Capital Management Ltd increased its stake in Sierra Wireless Inc (SWIR) by 10.74% based on its latest 2018Q3 regulatory filing with the SEC.
Jan 04, 2019. Read More

Rwc Asset Management Llp Has Decreased Its Lilly Eli & Co (LLY) Position; Harvard Bioscience (HBIO) Sentiment Is 1.66
Rwc Asset Management Llp decreased Lilly Eli & Co (LLY) stake by 32.71% reported in 2018Q3 SEC filing. Rwc Asset Management Llp sold 76399 shares as ...
Dec 25, 2018. Read More

Abbott Labs (ABT) Valuation Rose While Sector Gamma As Trimmed by $6.00 Million Its Holding; As Novartis Ag F Sponsored Adr 1 (NVS) Share Value Rose, Bourgeon Capital Management Has Raised Position
Sector Gamma As decreased its stake in Abbott Labs (ABT) by 7.73% based on its latest 2018Q3 regulatory filing with the SEC. Sector Gamma As sold 82250 ...
Dec 24, 2018. Read More

Bridges Investment Management Has Cut Its Halliburton Co Com (HAL) Position; Pictet Asset Management LTD Lowered Lilly Eli & Co (LLY) Stake
Bridges Investment Management Inc decreased Halliburton Co Com (HAL) stake by 27.99% reported in 2018Q3 SEC filing. Bridges Investment Management Inc ...
Dec 22, 2018. Read More

Lilly's Taltz Outshines Humira in Psoriatic Arthritis Study
Eli Lilly's (LLY) Taltz displays superiority over standard of care medicine Humira in a head-to-head study on patients with active psoriatic arthritis.
Dec 18, 2018. Read More

J&J’s Tremfya beats Novartis’ Cosentyx in a new phase 3 trial
Johnson & Johnson's psoriasis treatment Tremfya has reportedly been found more effective than Novartis's Cosentyx for treating moderate to severe stages of ...
Dec 14, 2018. Read More

J&J's Tremfya outperforms Novartis' Cosentyx in psoriasis
A large head-to-head study has shown Johnson & Johnson's psoriasis drug Tremfya outperformed Novartis' rival, Cosentyx, which had previously set standards ...
Dec 13, 2018. Read More

J&J's Tremfya Superior to Novartis' Cosentyx in Head-to-Head Trial
Tremfya was being compared to Novartis' Cosentyx (secukinumab) in a head-to-head study. In the trial, Tremfya showed that 84.5 percent of patients treated ...
Dec 12, 2018. Read More

Spherix Global Insights Reports Sun Dermatology's Ilumya Faces Challenges in A Crowded Psoriasis Market
EXTON, Pa., Dec. 5, 2018 /PRNewswire/ -- Spherix Global Insights' fourth quarter update of RealTime Dynamix™: Psoriasis (US), which includes the feedback ...
Dec 05, 2018. Read More

NICE okays UCB's Cimzia, nixes Almirall's Ilumetri, in psoriasis
NICE has recommended in draft guidance that UCB's Cimzia can receive regular NHS funding for plaque psoriasis, but decided that Almirall's rival Ilumetri does ...
Dec 05, 2018. Read More

Inside the Market Monday's analyst upgrades and downgrades
Inside the Market's roundup of some of today's key analyst actions.
Nov 26, 2018. Read More

More Rheumatologists are Using Pfizer's Xeljanz in Psoriatic Arthritis Patients, Outpacing the Impressive Growth Displayed by Eli Lilly's Taltz in the Previous Quarter
EXTON, Pa., Oct. 8, 2018 /PRNewswire/ -- The most recent quarterly results of a study conducted by Spherix Global Insights with 100 US rheumatologists ...
Oct 08, 2018. Read More

Lilly begins IXORA-R head-to-head trial for plaque psoriasis
Eli Lilly and Company (Lilly) has commenced the IXORA-R head-to-head (H2H) clinical trial to investigate the efficacy and safety of Taltz (ixekizumab) in ...
Sep 12, 2018. Read More

Lilly Announces Initiation of IXORA-R Head-to-Head Trial Comparing Taltz® and Tremfya® in Patients with Moderate-to-Severe Plaque Psoriasis
INDIANAPOLIS, Sept. 10, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the initiation of the IXORA-R head-to-head (H2H) clinical ...
Sep 10, 2018. Read More

Rheumatologist User Base for Eli Lilly's Taltz in Psoriatic Arthritis (PsA) Boasts Strong Growth in Q2, While Use of Pfizer's Xeljanz Has Remained Flat Over the Past Quarter
EXTON, Pa., July 17, 2018 /PRNewswire/ — The most recent quarterly results of a study conducted by Spherix Global Insights with 100 US rheumatologists ...
Jul 17, 2018. Read More

Johnson & Johnson, looking for its Tremfya niche, starts up new trial program in Crohn's
Johnson & Johnson immunology newcomer Tremfya is looking to follow in the footsteps of its big brother Stelara. The company launched a phase 2/3 clinical ...
Jul 11, 2018. Read More

Psoriatic arthritis data for Tremfya and Otezla presented at EULAR
Small molecule and biologic go head to head at the Annual European Congress of Rheumatology (EULAR) in Amsterdam on Friday morning, with oral ...
Jun 15, 2018. Read More

US Dermatologists Report Significant Growth of Next-Generation Psoriasis Biologics--Novartis' Cosentyx, Eli Lilly's Taltz, and Janssen's Tremfya
EXTON, Pa., June 12, 2018 /PRNewswire/ -- Spherix Global Insights' second quarter update of RealTime Dynamix™: Psoriasis (US) reveals significant changes ...
Jun 12, 2018. Read More

Next Generation Biologics, Janssen's Tremfya, Eli Lilly's Taltz, and Novartis' Cosentyx, Raising the Bar in Psoriasis Management
EXTON, Pa., March 8, 2018 /PRNewswire/ -- The past three years have brought with them a flurry of branded biologic approvals in dermatology, including four ...
Mar 08, 2018. Read More

For Cosentyx, Taltz, Siliq: A marketing race to differentiate
Cyndi Lauper counts herself as one of the 7.5 million Americans with psoriasis. Against the upbeat tempos of "Girls Just Wanna Have Fun" and heartfelt croons ...
Mar 07, 2018. Read More

Good News for Risankizumab, Tremfya, Otezla, and Taltz at AAD Meeting
Promising new findings in the treatment of plaque psoriasis, oral ulcers, and genital psoriasis have been reported at the 2018 American Academy of ...
Feb 19, 2018. Read More

Fresh data sets up showdown for Lilly's Taltz vs Cosentyx
Eli Lilly & Co. has in hand positive topline data from a Phase 3 study that evaluated its anti-inflammatory agent Taltz in a subset of patients with ankylosing ...
Feb 14, 2018. Read More

Tremfya for Plaque Psoriasis: What Pharmacists Should Know
This article highlights several key therapeutics areas with Tremfya that every pharmacist should know.
Jan 30, 2018. Read More



We may use cookies to give you the best experience. If you do nothing we'll assume that it's ok.

Terms & Privacy

The information forward from this site may be provided by third parties. We will not be responsible with outside links, contents from source of information, methods of using, using or consequence of contents with users. All direct or indirect risk related to use of this site is borne entirely by you, the user.

We use advertising companies as Google AdSense, to serve ads when you visit our website. These companies may use information (not including your name, address, email address, or telephone number) about your visits to this and other websites in order to provide advertisements about goods and services of interest to you. If you would like more information about this practice and to know your choices about not having this information used by these companies, see https://policies.google.com/technologies/ads.